Rosen Michael R, Brink Peter R, Cohen Ira S, Danilo Peter, Robinson Richard B, Rosen Amy B, Szabolcs Matthias J
Department of Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
J Interv Card Electrophysiol. 2008 Aug;22(2):87-98. doi: 10.1007/s10840-008-9208-3. Epub 2008 Mar 25.
The prevention and treatment of cardiac arrhythmias conferring major morbidity and mortality is far from optimal, and relies heavily on devices and drugs for the partial successes that have been seen. The greatest success has been in the use of electronic pacemakers to drive the hearts of patients having high degree heart block. Recent years have seen the beginnings of attempts to use novel approaches available through gene and cell therapies to treat both brady- and tachyarrhythmias. By far the most successful approaches to date have been seen in the development of biological pacemakers. However, the far more difficult problems posed by atrial fibrillation and ventricular tachycardia are now being addressed. In the following pages we review the approaches now in progress as well as the specific methodologic demands that must be met if these therapies are to be successful.
对导致重大发病率和死亡率的心律失常的防治远未达到最佳状态,并且在很大程度上依赖于设备和药物才取得了目前所见到的部分成效。最大的成功在于使用电子起搏器驱动患有高度心脏传导阻滞患者的心脏。近年来,已经开始尝试使用基因和细胞疗法提供的新方法来治疗缓慢性和快速性心律失常。迄今为止,最成功的方法是生物起搏器的研发。然而,目前正在解决心房颤动和室性心动过速带来的困难得多的问题。在接下来的几页中,我们将回顾目前正在进行的方法以及如果这些疗法要取得成功必须满足的具体方法学要求。